What Most Psychiatric Drug Development Programmes Learn Too Late: Six Questions That Determine Success

Psychiatric drug development is experiencing renewed momentum, driven by novel mechanisms and growing recognition of the unmet need for faster, more effective and safer pharmacological treatments. Yet scientific novelty does not eliminate familiar drug development risks. CHDR identifies four persistent bottlenecks limiting success in psychiatric drug development: uncertain disease biology, insufficient pharmacodynamic characterisation, reliance on phenomenology-based endpoints and commercial pressure to pursue broad diagnostic indications rather than biologically defined patient groups.¹

Question-Based Drug Development (QBDD) provides a framework for addressing these risks. Instead of allowing the conventional progression from Phase I to Phase III to dictate the scientific strategy, it begins with the uncertainties that must be resolved. Clinical studies, biomarkers and experimental models are then selected according to their ability to answer a specific question and support a development decision.² Six questions are particularly relevant in psychiatric CNS drug development.

1. Does the active compound reach its intended site of action?

Plasma exposure does not establish exposure within the brain. Blood–brain barrier permeability, active transport, regional distribution and pharmacologically active metabolites can all influence whether sufficient drug reaches the relevant receptor, cell type or neural circuit. Depending on the mechanism, evidence may come from cerebrospinal-fluid sampling, PET receptor-occupancy studies, pharmacokinetic modelling or demonstration of target engagement with a pharmacodynamic biomarker that is sensitive to the drug’s mechanism-of-action.³

This question must be answered before a negative clinical result can be interpreted accurately. If adequate target-site exposure has not been demonstrated, it remains impossible to distinguish an invalid therapeutic mechanism from inadequate delivery of the compound.

2. Does the compound produce its intended pharmacological and functional effects?

Brain penetration is necessary but not sufficient. The programme must demonstrate target engagement and show that this engagement produces functional pharmacodynamic effects in humans. CHDR conceptualises this as a cascade of events extending from drug-target interaction to molecular, electrophysiological effects and network adaptation, to functional CNS effects.³

CNS test batteries, (TMS-)EEG, functional MRI, neuroendocrine markers, cognitive and emotional-processing tasks, and pharmacological challenge models can provide supporting evidence. The objective is not merely to show that a dose was tolerated, but to quantify the relationships among exposure, target engagement, effect magnitude and effect duration. Proof of pharmacology in healthy participants can then support dose selection for proof of mechanism and proof of concept in psychiatric populations.

3. Does the compound produce unintended pharmacological or functional effects?

Psychiatric drugs frequently affect CNS functions beyond the intended therapeutic mechanism. Sedation, activation, anxiety, dissociation, cognitive impairment, sleep disruption, psychomotor dysfunction or emotional blunting may become clinically limiting before frank adverse effects are observed. These effects may be off-target, but they may also represent undesirable consequences of the intended mechanism.

Sensitive (neuro)physiological, cognitive, behavioural and subjective assessments should therefore be incorporated early and analysed in relation to exposure. This is particularly important for compounds with conspicuous psychoactive effects, which may compromise treatment masking and amplify expectancy effects. Unintended CNS effects are not simply entries in an adverse-event table; they help define the compound’s pharmacological profile and its potential clinical role.

4. Does the pharmacology translate into meaningful patient benefit?

A biomarker response is not equivalent to therapeutic efficacy. The programme should establish a coherent evidence chain:

dose → brain exposure → target engagement → functional CNS effect → clinical benefit

The final step is especially challenging in psychiatry because diagnostic categories are largely based on clusters of symptoms rather than specific biological mechanisms. Conventional rating scales remain essential, but they can be affected by placebo responses, rater variability, site effects and spontaneous symptom fluctuation. Changes in a mechanistic biomarker must therefore be connected to outcomes that matter to patients, such as symptom relief, improved functioning, sustained recovery or relapse prevention.

Early studies in carefully characterised patients can test this connection before a large efficacy trial. If adequate exposure and functional pharmacology are demonstrated without clinical benefit, the therapeutic hypothesis may be incorrect. If exposure and target engagement remain unknown, the same negative result reveals much less.

5. Is there a clinically useful therapeutic window?

Desired and undesired effects must be evaluated within the same exposure–response framework. The appropriate dose is not necessarily the maximum tolerated dose. It is the dose that provides sufficient target engagement and functional activity while maintaining an acceptable margin for safety and tolerability.

This balance is particularly important in psychiatry, where cognitive, emotional, psychomotor and sleep-related effects may influence adherence and long-term functioning. For rapidly acting or intermittently administered psychoactive treatments, the intensity and duration of acute effects must also be evaluated against the magnitude and persistence of therapeutic benefit. Integrating pharmacokinetic, pharmacodynamic, safety and functional data early can establish whether a viable therapeutic window exists before large patient trials begin.

6. How will variability in the target population affect response?

Patients sharing the same psychiatric diagnosis may differ substantially in underlying biology, symptom dimensions, disease stage, treatment history, comorbidities, concomitant medication and drug exposure. A compound may therefore be pharmacologically active yet appear ineffective when tested across a heterogeneous diagnostic population.

Biomarker-based stratification, pharmacogenetics, deep phenotyping and pharmacometric modelling can identify factors associated with response, non-response and adverse effects. Adaptive designs may allow dosing or enrolment criteria to be refined as evidence accumulates. Although broad indications may appear commercially attractive, narrowly defined populations with a strong mechanistic rationale can provide clearer evidence and a more credible route to clinical benefit.¹

The QBDD framework questions do not represent a new sequence of drug development phases. In addition, their priority depends on the compound, mechanism-of-action, indication and principal source of uncertainty. A data-rich early study may answer several questions simultaneously, while a critical uncertainty may require multiple complementary experiments. The next study should be selected because its result will change a decision, not simply because it is the conventional next step.

What psychiatric drug development programmes often learn too late is that completing a clinical phase is not the same as reducing uncertainty. A successful programme makes it progressively easier to distinguish failure of the molecule from failure of the mechanism, dose, endpoint or selected population. An early, evidence-based decision to stop may therefore represent success. The most damaging outcome is not failure itself, but failure after the programme has invested heavily without answering the questions that determined its prospects from the beginning.

References

1. Centre for Human Drug Research. Psychiatric Drug Development Renaissance: With Familiar Risks. Clinical Leader, 6 January 2026. Read the article

2. Cohen AF, Burggraaf J, van Gerven JMA, Moerland M, Groeneveld GJ. The use of biomarkers in human pharmacology (Phase I) studies. Annual Review of Pharmacology and Toxicology. 2015;55:55–74. PubMed

3. Centre for Human Drug Research. Psychiatry: biomarker-driven early drug development. CHDR